1. Goessling W, Massaro JM, Vasan RS, D'Agostino RB, Sr., Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008;135:1935–44. 1944 e1931.
2. Schneider AL, Lazo M, Ndumele CE, Pankow JS, Coresh J, Clark JM, et al. Liver enzymes, race, gender and diabetes risk: The atherosclerosis risk in communities (aric) study. Diabetic medicine: a journal of the British Diabetic Association. 2013;30:926–33.
3. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: The insulin resistance atherosclerosis study. Diabetes. 2005;54:3140–7.
4. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, et al. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the hoorn study. Atherosclerosis. 2007;191:391–6.
5. Gao M, Cheng Y, Zheng Y, Zhang W, Wang L, Qin L. Association of serum transaminases with short- and long-term outcomes in patients with st-elevation myocardial infarction undergoing primary percutaneous coronary intervention. BMC Cardiovasc Disord. 2017;17:43.
6. Monami M, Bardini G, Lamanna C, Pala L, Cresci B, Francesconi P, et al. Liver enzymes and risk of diabetes and cardiovascular disease: Results of the firenze bagno a ripoli (fibar) study. Metabolism. 2008;57:387–92.
7. Ford I, Mooijaart SP, Lloyd S, Murray HM, Westendorp RG, de Craen AJ, et al. The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. Int J Epidemiol. 2011;40:1530–8.
8. Ruhl CE, Everhart JE. The association of low serum alanine aminotransferase activity with mortality in the us population. Am J Epidemiol. 2013;178:1702–11.
9. Williams KH, Sullivan DR, Veillard AS, O'Brien R, George J, Jenkins AJ, et al. Low alanine aminotransferase levels and higher number of cardiovascular events in people with type 2 diabetes: Analysis of the fenofibrate intervention and event lowering in diabetes (field) study. Diabetic medicine: a journal of the British Diabetic Association. 2016;33:356–64.
10. Harada PH, Cook NR, Cohen DE, Paynter NP, Rose L, Ridker PM. Relation of alanine aminotransferase levels to cardiovascular events and statin efficacy. Am J Cardiol. 2016;118:49–55.
11. Kim HC, Kang DR, Nam CM, Hur NW, Shim JS, Jee SH, et al. Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage: Korea medical insurance corporation study. Stroke. 2005;36:1642–7.
12. Lee TH, Kim WR, Benson JT, Therneau TM, Melton LJ. 3rd. Serum aminotransferase activity and mortality risk in a united states community. Hepatology 2008;47:880–7.
13. Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Blokzijl H, Gansevoort RT, Dullaart RP. Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: The prevend study. Atherosclerosis. 2015;243:138–47.
14. Kunutsor SK, Apekey TA, Seddoh D, Walley J. Liver enzymes and risk of all-cause mortality in general populations: A systematic review and meta-analysis. Int J Epidemiol. 2014;43:187–201.
15. Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studies. Atherosclerosis. 2014;236:7–17.
16. Wang Y, Cui L, Ji X, Dong Q, Zeng J, Wang Y, et al. The china national stroke registry for patients with acute cerebrovascular events: Design, rationale, and baseline patient characteristics. Int J Stroke. 2011;6:355–61.
17. Schumann G, Bonora R, Ceriotti F, Ferard G, Ferrero CA, Franck PF, et al. Ifcc primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees c. International federation of clinical chemistry and laboratory medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med. 2002;40:718–24.
18. Schumann G, Bonora R, Ceriotti F, Ferard G, Ferrero CA, Franck PF, et al. Ifcc primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees c. International federation of clinical chemistry and laboratory medicine. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. Clin Chem Lab Med. 2002;40:725–33.
19. Ratziu V, Imbert-Bismut F, Messous D, Poynard T. The elusiveness of "normal" alt in fatty liver. Hepatology. 2004;39:1172.
20. Pacifico L, Ferraro F, Bonci E, Anania C, Romaggioli S, Chiesa C. Upper limit of normal for alanine aminotransferase: Quo vadis? Clin Chim Acta. 2013;422:29–39.
21. Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM. The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: The insulin resistance atherosclerosis study. Diabetologia. 2013;56:746–57.
22. Siddiqui MS, Sterling RK, Luketic VA, Puri P, Stravitz RT, Bouneva I, et al. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology. 2013;145:1271–9.e1271-1273.
23. Schooling CM, Kelvin EA, Jones HE. Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in nhanes iii. Ann Epidemiol. 2012;22:789–98.
24. DG LEC, Cogger VC, McCuskey RS, Smedsrod RDEC, Sorensen B. KK, et al. Age-related changes in the liver sinusoidal endothelium: A mechanism for dyslipidemia. Ann N Y Acad Sci. 2007;1114:79–87.
25. Dong MH, Bettencourt R, Brenner DA, Barrett-Connor E, Loomba R. Serum levels of alanine aminotransferase decrease with age in longitudinal analysis. Clin Gastroenterol Hepatol 2012;10:285–90 e281.
26. Schmucker DL. Age-related changes in liver structure and function: Implications for disease ? Exp Gerontol. 2005;40:650–9.
27. Le Couteur DG, Blyth FM, Creasey HM, Handelsman DJ, Naganathan V, Sambrook PN, et al. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol A Biol Sci Med Sci. 2010;65:712–7.
28. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–50.
29. Ioannou GN. Implications of elevated serum alanine aminotransferase levels: Think outside the liver. Gastroenterology. 2008;135:1851–4.
30. Campos F, Rodriguez-Yanez M, Castellanos M, Arias S, Perez-Mato M, Sobrino T, et al. Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels. Clin Sci (Lond). 2011;121:11–7.
31. Campos F, Sobrino T, Ramos-Cabrer P, Castellanos M, Blanco M, Rodriguez-Yanez M, et al. High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke. J Cereb Blood Flow Metab. 2011;31:1387–93.